Nicotinic acetylcholine receptors (nAChRs) are a diverse family of the larger Cys-loop superfamily of ligand gated ion channels (LIGCs). These channels are found throughout the brain and CNS and play vital roles in the chemical and electrical communication between neurons, contributing to memory, learning, and other neural functions.^[@ref1]−[@ref3]^ Because of their diverse properties and widespread distribution throughout the brain, these LGICs are prominent targets in neurological disorders, such as drug addiction, Alzheimer's disease, and Parkinson's disease.^[@ref4],[@ref5]^

Neuronal nAChRs have been extensively studied and much is known about their assembly and structure.^[@ref2],[@ref6]−[@ref8]^ There are two classes of subunits, identified as α2−α9 and β2−β4, which assemble into homomeric (α only) or heteromeric (α and β) channels consisting of five subunits in total.^[@ref9]^ For each subunit, there is a main agonist binding pocket, denoted as the primary (+) face, which includes four of the five residues that make up the canonical "aromatic box".^[@ref10]^ The fifth aromatic box residue and other key binding residues, including backbone contacts, are found on the complementary (−) face of the adjacent subunit.^[@ref10]^ The five subunits then arrange in an alternating + and -- fashion to form a functional receptor (Figure [1](#fig1){ref-type="fig"}A). For decades it has been assumed that the (+) face of the agonist binding site is provided by α subunits and the (−) face by β subunits. However, recent evidence establishes the ability of α subunits to also contribute the (−) face.

![(A) View from the extracellular side of the high affinity (A2B3) and low affinity (A3B2) α4β2 receptors. Agonist binding locations are indicated by smaller circles at the interfaces of α4−β2 subunits and α4−α4 subunits. (B) Sequence alignment of the rat muscle and neuronal nAChR subunits. The three residues that greatly influence agonist affinity are highlighted in gray. (C) Structures of sazetidine-A, cytisine, and NS9283.](cb-2013-00937d_0002){#fig1}

The core pharmacophore of a cationic nitrogen and a hydrogen bond acceptor for agonists of the nAChR was first introduced in 1970.^[@ref11]^ Since then, the binding model has evolved to consist of three specific interactions that include a cation−π interaction on the primary subunit, along with hydrogen bonding interactions on both the primary and complementary subunits.^[@ref12],[@ref13]^ Based on this model, a number of studies have aimed to explain the efficacies and selectivities of agonists to different nAChRs of varying subunits and stoichiometries.^[@ref12]−[@ref14]^

Here, we studied the activation profiles of α4β2 receptors and their responses to mutations for the following compounds: sazetidine-A, cytisine, and NS9283 (Figure [1](#fig1){ref-type="fig"}C). Our conclusions lead us to propose an expansion of the published structural models.^[@ref10],[@ref12],[@ref15],[@ref16]^ We establish that (1) the selectivity of drug binding at subunit interfaces is largely controlled by a pocket on the complementary subunit that is hydrophobic in some subunits and hydrophilic in others and (2) an agonist must be bound at all α subunits in a given receptor to favor the activated channel. This expansion aids in our understanding of subunit- and stoichiometry-selective agents and can provide valuable insight for further development and application toward therapeutic strategies.

Results and Discussion {#sec2}
======================

Hydrogen Bonding: Unnatural Amino Acid Analysis {#sec2.1}
-----------------------------------------------

Sazetidine-A has a unique activation profile, in that it selectively activates the (α4)~2~(β2)~3~ stoichiometry over the (α4)~3~(β2)~2~; these stoichiometries will be abbreviated A2B3 and A3B2, respectively.^[@ref17]^ Unnatural amino acids are useful tools used to parse out specific chemical interactions between ligand and receptor. Previous structure--function studies of cytisine, an agonist that has the opposite activation profile for α4β2 receptors, showed that the active drug-receptor combination (A3B2) favored the hydrogen bond to the TrpB backbone CO ("donor"), while the inactive form favored the hydrogen bond to the backbone NH on the complementary face ("acceptor") (Table [1](#tbl1){ref-type="other"} and Figure [2](#fig2){ref-type="fig"}A).^[@ref12]^ We proposed that this difference could explain the stoichiometry selectivity of the drug. Through unnatural amino acid incorporation, we were able to characterize the cation-π binding, hydrogen bond-donating, and hydrogen-bond accepting properties of sazetidine-A and compare the results to those previously measured for cytisine. We now find, however, that the opposite hydrogen bonding pattern is not seen for sazetidine-A and that the pattern roughly follows the one observed for cytisine: a larger affect for the hydrogen-bonding acceptor in the A2B3 stoichiometry and a larger affect for the hydrogen-bonding donor in the A3B2 stoichiometry (Table[1](#tbl1){ref-type="other"} and Figure [2](#fig2){ref-type="fig"}A). This pattern suggests an alternative explanation is needed to identify the properties of stoichiometry selective agonists.

![Binding models of sazetidine-A and analogs. (A) Binding model for sazetidine-A based on established interactions seen with nicotine. ([@ref12]) The cation−π interaction is in purple, the hydrogen bond donor is in red, and the hydrogen bond acceptor is in green. (B) Crystal structure showing a sazetidine-A analog bound to Ct-AChBP (PDB: 4B5D).^[@ref15]^ The three key residues identified for the hydrophobic pocket associated with the β2 subunit (V109, F117, and L119) are shown as is the TrpB residue from the α4 subunit. These residues were mutated into the crystal structure to show general spatial locations (no residue minimizations calculated).](cb-2013-00937d_0003){#fig2}

###### Agonist Binding Model Comparison

![](cb-2013-00937d_0006){#fx1}

See [Methods](#sec4){ref-type="other"} for wild type EC~50~ corrections.

Ratio of *I*~max~ of compound divided by *I*~max~ of acetylcholine.

Ratio of EC~50~ values for 4,5,6,7-tetraflouro-Trp and Trp incorporation at α4 W154 (Figure [2](#fig2){ref-type="fig"}A).

Ratio of EC~50~ values for Thr-α-hydroxy and Thr incorporation at α4 T155 (Figure [2](#fig2){ref-type="fig"}A).

Ratio of EC~50~ values for Leu-α-hydroxy and Leu incorporation at β2 L119 (Figure [2](#fig2){ref-type="fig"}A).

Previously reported values from Tavares et al.^[@ref12]^

Measured EC~50~ values reported in the [SI Table 1](#notes-1){ref-type="notes"}.

Sazetidine-A and the β2 Complementary Face {#sec2.2}
------------------------------------------

It has been shown that the unique hydrophobic appendage off of the pyridine ring of sazetidine-A gives the compound its subunit and receptor selectivity and that the alcohol group at the end of the appendage does not play a significant role.^[@ref15],[@ref18],[@ref19]^ Because this aliphatic adjunct interacts mostly with the complementary side, we began by focusing on the known differences between α4 and β2 subunits in this region.^[@ref16]^ Previous investigations identified an α4−α4 binding site and suggested the differences between the "high" affinity (α4−β2) and "low" affinity (α4−α4) binding pockets are due to three key residues that reside on the complementary face.^[@ref20]−[@ref22]^ The β2(−) face residues (V109, F117, and L119) generate a hydrophobic pocket for the high affinity case, while the aligning α4(−) face residues (H114, Q122, and T124) create a hydrophilic, low affinity pocket (Figure [1](#fig1){ref-type="fig"}B and Figure [2](#fig2){ref-type="fig"}B). We have evaluated the triple mutant of the α4(−) face by swapping these three residues (H114V, Q122F, and T124L) to make them resemble the β2(−) face. We were able to generate receptor responses and measure an EC~50~ curve for sazetidine-A in the A3B2 receptor, which was not possible with the wild type α4 subunit (Figure [3](#fig3){ref-type="fig"}) (Table [2](#tbl2){ref-type="other"}). The EC~50~ value for the triple mutant was about 5-fold larger than the wild type A2B3 response, a small difference compared to having zero response in the wild type A3B2 receptor. Single mutations at the α4 subunit did not give rise to sazetidne-A response at low μM doses ([SI Table 2](#notes-1){ref-type="notes"}). Combinations of double mutations saw some response to low μM doses of sazetidine-A ([SI Table 2](#notes-1){ref-type="notes"}). Mutations to make the β subunit more like the α subunit resulted in a large loss of function for sazetidine-A ([SI Table 3](#notes-1){ref-type="notes"}).

![Sazetidine-A EC~50~ curves. (α4)~3~(β2)~2~ cannot be activated by sazetidine-A. Responses can be obtained by mutating the complementary side of the α4 subunit to resemble the β2 subunit as seen with (α4 H114V, Q122F, T124L)~3~(β2)~2~ receptor. Also shown is wild type (α4)~3~(β2)~2~ receptor exposed to a combination of sazetidine-A and NS9283.](cb-2013-00937d_0004){#fig3}

###### Sazetidine-A EC~50~ (nM) Values

  receptor                             EC~50~ (nM)   Hill        *n*   *I*~max~ (μA)
  ------------------------------------ ------------- ----------- ----- ---------------
  (α4)~2~(β2)~3~                       1.9 ± 0.1     2.0 ± 0.2   14    0.059--0.26
  (α4)~3~(β2)~2~                       NR                               
  (α4)~**2**~(β2)~3~ + 10 μM NS9283    2.0 ± 0.2     1.7 ± 0.2   13    0.067--1.6
  (α4)~3~(β2)~2~ + 10 μM NS9283        1.1 ± 0.1     2.0 ± 0.2   14    0.4--7.2
  (α4 H114V, Q122F, T124L)~2~(β2)~3~   4.8 ± 0.3     1.8 ± 0.2   13    0.18--1.3
  (α4 H114V, Q122F, T124L)~3~(β2)~2~   9 ± 1         2.3 ± 0.6   14    0.71--6.2

Agonist = Sazetidine-A.

NR = No Response.

Cytisine and the β2 Complementary Face {#sec2.3}
--------------------------------------

Since these three residues had a large affect on receptor agonist selectivity and activation for sazetidine-A, we considered cytisine in an attempt to explain its selectivity for A3B2 over A2B3 receptors. Early chimera analysis showed that cytisine selectivity for human β4 over β2 subunits is strongly influenced by the extracellular region,^[@ref23]^ and more recent analyses provide further details.^[@ref24]^ Sequence alignment shows that of the three residues considered here, the only difference lies in the 117 position -- β2 F117 and β4 L117 for the human subunits. For the rodent subunits considered here, β4 is Q117, which is identical to the α4 residue at this same position (Figure [1](#fig1){ref-type="fig"}). In the rodent wild type α4β2 receptors, cytisine is a partial agonist with a biphasic response for the A3B2 receptor. No response is observed for the A2B3 receptor (Table [3](#tbl3){ref-type="other"}), although signal can be obtained in receptors with hypersensitive mutations (see [Methods](#sec4){ref-type="other"}). However, with the single mutation of F117Q in the β2 subunit, cytisine generated a sizable response for the A2B3 receptor. The mutation also raised the efficacy of the A3B2 receptor compared to the wild type response (Table [3](#tbl3){ref-type="other"}).

###### Cytisine-A EC~50~ (μM) Values

  receptor               EC~50~ (μM) \[1\]   Hill \[1\]   EC~50~ (μM) \[2\]   Hill \[2\]   \% \[1\]   *n*   Cyt *I*~max~ (μA)   ACh *I*~max~ (μA)   efficacy
  ---------------------- ------------------- ------------ ------------------- ------------ ---------- ----- ------------------- ------------------- -----------
  (α4)~2~(β2)~3~         NR                                                                                                     0.15--2.4            
  (α4)~3~(β2)~2~         0.047 ± 0.005       1.8 ± 0.3    6.0 ± 0.3           1.3 ± 0.1    22         16    0.052--2.9          0.94--33            7 ± 0.1%
  (α4)~2~(β2 F117Q)~3~   0.019 ± 0.001       1.6 ± 0.1                                                11    0.026--0.10         0.084--2.5          22 ± 0.1%
  (α4)~3~(β2 F117Q)~2~   0.03 ± 0.01         1.0 ± 0.3    3.3 ± 0.7           1.1 ± 0.2    33         17    0.055--4.0          0.51--20            16 ± 0.3%

Agonist = Cytisine.

NR = No Response.

NS9283 and the α4 Complementary Face {#sec2.4}
------------------------------------

We next considered NS9283, which has a binding preference for the α4−α4 interface.^[@ref25]^ This compound has been previously characterized as a benzodiazepine-like positive allosteric modulator (PAM) for only the A3B2 stoichiometry of receptors containing either α2 or α4 subunits.^[@ref25],[@ref26]^ In addition, its effects are lost when the α4(−) face is mutated to resemble the β2(−) face in the region of the classical agonist binding site.^[@ref27]^ Since we have molecules that selectively associate with α4−α4 (NS9283) and α4−β2 (sazetidine-A) interfaces, coapplication should generate an A3B2 receptor response. As shown in Figures [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"} and Table [2](#tbl2){ref-type="other"}, we find that individual applications of NS9283 and sazetidine-A show essentially no activation of wild type A3B2 receptors. However, coapplication generates full activation of the receptor, compared to acetylcholine. The A3B2 α4 triple mutant (H114V, Q122F, T124L) was then exposed to similar conditions. The sazetidine-A response for the mutant was preserved, but the effect of NS9283 was completely lost (Figure [4](#fig4){ref-type="fig"}) (Table [2](#tbl2){ref-type="other"}). The mutations eliminate the ability of NS9283 to bind at the α4−α4 interface and allow sazetidine-A to replace it in binding. These data suggest that occupation of an agonist at each α subunit is necessary for a receptor response. We generated the A3B2 β2 triple mutant (V109H, F117Q, L119T) to test if NS9283 could alone activate the channel. A response was seen in a dose dependent manner, suggesting the drug is a partial agonist, albeit, not potent or highly efficacious (Figure [4](#fig4){ref-type="fig"}). Because NS9283 is sparingly soluble, a full EC~50~ curve could not be obtained. Nevertheless, we were able to transform a compound once designated as a PAM into an agonist, suggesting it could be binding to the canonical aromatic binding site. Also, due to its low potency and lower receptor expression, the corresponding A2B3 β2 triple mutant (V109H, F117Q, L119T) was inconclusive with regard to activation via NS9283.

![Sample traces of responses to acetylcholine (ACh), sazetidine-A (Saz-A), and NS9283 (NS) to A3B2 receptors. Solid gray bars indicate drug application and dashed bars indicate a pause where drug remains present but the buffer wash has not started. Gaps between traces indicate buffer washes (see [Methods](#sec4){ref-type="other"} for duration of drug application and buffer washes). (A) Activation of wild type receptor by ACh at its EC~50~ value and Saz-A and NS at the concentrations shown. (B) Activation of (α4 H144 V, Q122F, T124L)~3~(β2)~2~. (C) Application of *I*~max~ concentrations of acetylcholine and two concentrations of NS to (α4)~3~(β2 V109H, F117Q, L119T)~2~. The \* indicates a 1% by volume DMSO drug solution.](cb-2013-00937d_0005){#fig4}

Conclusions {#sec3}
===========

The present work confirms and expands upon recent studies on the (−), complementary face of the agonist binding site of nAChRs. In particular, the long-held belief that agonist binding sites are formed only at α(+)/β(−) interfaces has been challenged by increasing evidence for a viable agonist binding site at α(+)/α(−) interfaces. Here we use several drugs that show some subtype specificity to probe this issue. The novel agonist sazetidine-A can only activate α4β2 receptors with an A2B3 stoichiometry. In the alternative A3B2 stoichiometry, an α(+)/α(−) interface exists. The (−) face of such an interface is relatively polar, and evidently it is incompatible with the hydrophobic side chain of sazetidine-A that is expected to project into this region (recall that the OH group of sazetidine-A is not necessary for function). By mutating three residues in this region to be more hydrophobic and thus more like a β2(−) face, we can prepare A3B2 receptors that are quite responsive to sazetidine-A (Table [2](#tbl2){ref-type="other"}).

In a complementary series of experiments, we considered the drug NS9283, which binds only to α(+)/α(−) interfaces. It is unable to activate the receptor on its own, and it is thus an allosteric modulator. We reasoned that a combination of NS9283 and sazetidine-A would activate A3B2 receptors, with the former binding to the α(+)/α(−) interface and the latter to the α(+)/β(−) interfaces. Indeed, a mixture of NS9283 and sazetidine-A is quite potent at A3B2 receptors, while neither compound alone can activate the receptor. Taking this one step further, by mutating all interfaces so they resemble α(+)/α(−) interfaces, NS9283 becomes an agonist, rather than the allosteric modulator it is for the wild type receptor.

We also applied this interface concept to cytisine, which has the reverse activation profile of sazetidine-A, in that it cannot activate the A2B3 receptor. By mutating one residue of the β2 subunit to that of the α4 subunit, we find that cytisine can activate the A2B3 receptor. In addition, this same mutation increased efficacy of cytisine for the A3B2 receptor from 7% to 16% (Table [3](#tbl3){ref-type="other"}).

In sum, this work shows the relevance of the α(+)/α(−) interface of nAChRs to achieving full receptor activation. This knowledge could be of great value to efforts to develop selective agonists for specific nAChR subtypes.

Methods {#sec4}
=======

Molecular Biology {#sec4.1}
-----------------

Rat nAChR α4 and β2 subunits were in pAMV (unnatural mutagenesis) and pGEMhe (natural mutagenesis) vectors. Site-directed mutagenesis was performed using the QuikChange protocol (Stratagene). Circular DNA of α4 and β2 in pAMV was linearized with the NotI restriction enzyme and the plasmids in pGEMhe were linearized with the SbfI restriction enzyme. After purification (Qiagen), the T7 mMessage Machine kit (Ambion) was used to *in vitro* transcribe mRNA from linearized DNA templates. QIAGEN's RNeasy RNA purification kit was used to isolate the transcribed mRNA product.

For unnatural amino acid incorporation, the amber (UAG) stop codon was used for all α4 subunit incorporation and the opal (UGA) stop codon was used for the β2 subunit incorporation. 74-nucleotide THG73 tRNA (for UAG) and 74-nucleotide TQOpS' tRNA (for UGA) were *in vitro* transcribed using the MEGAshortscript T7 (Ambion) kit and isolated using Chroma Spin DEPC-H~2~O columns (Clontech). Synthesized unnatural amino acids coupled to the dinucleotide dCA were enzymatically ligated to the appropriate 74-nucleotide tRNA as previously described.^[@ref13],[@ref28]^

Oocyte Preparation and Injection {#sec4.2}
--------------------------------

*Xenopus laevis* stage V and VI oocytes were harvested via standard protocols.^[@ref28]^ For unnatural amino acid incorporation to the α-subunit, the α4 and β2 mRNAs were mixed in a 3:1 ratio by mass to obtain the A2B3 receptor, and in a 100:1 ratio to obtain the A3B2 receptor. Unnatural amino acid incorporation to the β-subunit used α4 and β2 mRNA ratios of 1:20 and 10:1 to obtain the A2B3 and A3B2 receptors, respectively. mRNA mixtures and deprotected (photolysis) tRNA were mixed in a 1:1 volume ratio, and 50 nl were injected into each oocyte. After injection, the oocytes were incubated at 18 °C in ND96+ medium for 24 h. For the unnatural amino acids with reduced cation-π binding ability, a second round of injections following the same procedure was performed followed by incubation for an additional 24 h. The reliability of the unnatural amino acid incorporation was confirmed through read-through/reaminoacylation tests as previously performed.^[@ref12]^

For the natural mutagenesis experiments, the α4 and β2 mRNAs were mixed in 1:2 or 10:1 ratios by mass to obtain the A2B3 and A3B2 receptors, respectively.^[@ref29]^ A total of 50 nL were injected to each oocyte, delivering a mRNA mass total of 25 ng. Oocytes were incubated at 18 °C in ND96+ medium for 24--72 h.

Chemical Preparation {#sec4.3}
--------------------

Acetylcholine chloride was purchased from Sigma-Aldrich and dissolved to 1 M stock solutions in ND96 Ca^2+^ free buffer (96 mM NaCl, 2 mM KCl, 1 mM MgCl~2~, 5 mM HEPES at pH 7.5). Sazetidine-A dihydrochloride and (−)-cytisine were purchased from Tocris Bioscience and dissolved to 10 mM stock solutions in ND96 Ca^2+^ free buffer.

NS9283 was synthesized following a patented protocol.^[@ref30]^ 3-Pyridylamidoxime and 3-cyanobenzoyl chloride were purchase from Sigma-Aldrich. 3-Pyridylamidoxime (0.5 g) was dissolved in 5.4 mL of pyridine. Then, 0.6 g of 3-cyanobenzoyl chloride was added while stirring. The mixture was heated at reflux for 90 min and then cooled to RT. 200 mL of water was added and the white powder was filtered with two subsequent washes with water. The resulting powder was lyophilized overnight to remove the excess water. The reaction resulted in 60% yield, and the product was pure by LC-MS and NMR. ^1^H NMR (300 MHz, DMSO-*d*~6~) δ 9.26 (dd, *J* = 2.2, 0.9 Hz, 1H), 8.82 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.64 (td, *J* = 1.7, 0.7 Hz, 1H), 8.50 (ddd, *J* = 8.0, 1.9, 1.1 Hz, 1H), 8.47 (dt, *J* = 6.0, 2.1 Hz, 1H), 8.22 (dt, *J* = 7.9, 1.4 Hz, 1H), 7.88 (td, *J* = 7.9, 0.7 Hz, 1H), 7.65 (ddd, *J* = 7.9, 4.8, 0.9 Hz, 1H); MS (+ES-API) *m*/*z* 249 (M+H)^+^.

The purified compound, NS9283, was then dissolved to a 10 mM stock solution in DMSO. All drug solutions containing NS9283 were 0.1% DMSO (v/v) with the exception of the 100 μM dose, which had 1% DMSO (v/v). Appropriate controls of 1% DMSO (v/v) in ND96 Ca^2+^ free buffer only were applied to expressing cells to show no receptor response to the higher DMSO concentration.

Electrophysiology {#sec4.4}
-----------------

The OpusXpress 6000A (Axon Instruments) in two-electrode voltage clamp mode was used for all electrophysiological recordings. The holding potential was set to −60 mV, and the running buffer used was ND96 Ca^2+^ free solution for all experiments. All acetylcholine drug applications used 1 mL of drug solution applied over 15 s followed by a 2.5 min buffer wash at a rate of 3 mL min^--1^. All sazetidine-A, cytisine, NS9283, and coapplications used 1 mL of drug solution applied over 8 s with a 30 s pause before a 5 min buffer wash at a rate of 3 mL min^--1^. Dose--response measurements utilized a series of ∼3-fold concentration steps, spanning several orders of magnitude, for a total of 8 to 18 doses. Data were sampled at 50 Hz and then low-passed filtered at 5 Hz. Experiments testing activity of compounds involved two to three acetylcholine doses of either EC~50~ or *I*~max~ values, followed by the test doses of compounds being probed, followed by one to two doses of the previous acetylcholine concentrations.

Averaged and normalized data were fit to one or two Hill terms to generate EC~50~ and Hill coefficient (nH) values. All currents for the activity testing were normalized to the highest acetylcholine dose applied precompound testing. The efficacy of compounds was measured as the ratio of the *I*~max~ of the compound divided by the *I*~max~ of acetylcholine. All acetylcholine EC~50~ values for the conventional mutations made in pGEMhe are reported in ([SI Table 4](#notes-1){ref-type="notes"}). Error bars represent standard error of the mean (SEM) values.

Hypersensitive Mutation (L9′A) {#sec4.5}
------------------------------

In the case of unnatural amino acid incorporation and mutagenesis scanning, EC~50~ values were obtained using a hypersensitive mutation in the α4 subunit (L9′A). This mutation serves two purposes in the experimental setup: (1) the gain of function mutation gives a larger concentration window to probe effects of introduced mutations and (2) the pore mutation causes differences in rectification between the two stoichiometries, which can be probed via voltage jump experiments to confirm which stoichiometry is being observed.^[@ref13],[@ref31]^ Since the EC~50~ is shifted from true wild type, a correction factor was applied according to the procedure of Moroni et al. to obtain the wild type EC~50~ value.^[@ref32]^

Additional tables as described in the text. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Supplementary Material
======================

###### 

cb400937d_si_001.pdf

The authors declare no competing financial interest.

We thank the National Institutes of Health (NIH) (NS034407, DA017279, DA280382), NIH/NRSA (GM07616), and the California Tobacco-Related Disease Research Program from the University of California (19XT-0102) for support of this work.
